Enterosgel Clinically Proven
Enterosgel well known anti-toxins gastro-absorbent.
To see publications please follow the link PUBMED Enterosgel
Enterosgel Protection is a way to insure our customers that all investments (spending’s) in Enterosgel would value for all families in New Zealand and Australia. We insure our customers that all unopened Enterosgel tubes will be replaced for another 3 years protection without any extra payment. We wish that our customers would never regret investing money to Enterosgel Protection.
This is our next step to say THANK YOU to all our loyal customers.
Enterosgel, batch #L309170051, has been tested by the Britain National Measurement Laboratory and Designated Institute (LGC) for a wide range of substances banned by WADA (the World Anti Doping Agency) to provide the highest level of assurance that they are safer for athletes to use.
LGC is a World Class sports doping control and research laboratory, with more than 50 years of leadership in drug surveillance in sport.
Ryan Bellone | Business Development Manager | Sport and Specialized Analytical Services | Standards | Mobile: +1 206-452-4948 | email@example.com | Skype: lgc.ryan.bellone |
LGC Lexington | 1745 Alysheba Way, Suite 160 | Lexington | Kentucky | 40509 | USA |
LGC Fordham | Newmarket Road | Fordham | Cambridgeshire | CB7 5WW | UK |
informed-choice.org | informed-sport.com | lgcgroup.com
Irrespective of the type of diarrhoea, probiotics, enterosorbents and medications of immunomodulatory action should be considered alternative to antibiotics and chemotherapeutic agents for starting etiotropic therapy of mild, moderate, even severe forms of Acute intestinal infections in children (under condition of starting treatment on day 1-2 of the disease).
Enterosgel is an intestinal absorbent (enterosorbent) intended to be used as an adjuvant to standard rehydration therapy and in the management and reduction of stomach and intestinal illness symptoms.
T.L. Protsyuk, N.I. Tocarchuk, L.A. Protsyuk, О. V. Chirkа, N.M. Surkovа, L.D. Kotsur
National Pirogov Memorial Medical University, Vinnytsya Regional Children’s Clinical Hospital
MATERIAL AND METHODS OF THE STUDY
90 infants in the first year of life with severe (45 patients) and moderate (45 patients) atopic dermatitis (group 1) and 50 patients in the first year of life with mild forms of atopic dermatitis – (group 2) were examined. Follow-ups of children were carried out during 4 years.